---
title: "Predictive Oncology Inc. Reports Q1 2025 Loss of $2.3 Million on Revenue of $110,310"
description: "Predictive Oncology Inc. reported a Q1 2025 loss of $2.3 million on revenue of $110,310, a significant increase from $4,858 in Q1 2024. The revenue growth was driven by the completion of a tumor-speci"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240356312.md"
published_at: "2025-05-15T11:04:51.000Z"
---

# Predictive Oncology Inc. Reports Q1 2025 Loss of $2.3 Million on Revenue of $110,310

> Predictive Oncology Inc. reported a Q1 2025 loss of $2.3 million on revenue of $110,310, a significant increase from $4,858 in Q1 2024. The revenue growth was driven by the completion of a tumor-specific 3D model. The company ended the quarter with $3.1 million in cash, up from $611,822 at the end of 2024. Predictive Oncology also partnered with Tecan Group to enhance drug screening capabilities and is seeking collaborations with biopharmaceutical firms for drug repurposing using AI and machine learning.

Predictive Oncology Inc. (Nasdaq: POAI) reported its financial results for the first quarter of 2025, ending March 31. The company recorded total revenue of $110,310, a significant increase from the $4,858 reported during the same period in 2024. This rise in revenue was primarily attributed to the completion of a tumor-specific 3D model within the quarter. The company reported a loss from continuing operations of approximately $2.3 million. Basic and diluted loss per common share from continuing operations for the quarter was $0.32, compared to $0.88 for the same period in 2024. Predictive Oncology concluded the quarter with $3.1 million in cash and cash equivalents, a substantial increase from $611,822 as of December 31, 2024. The company also reported an improved Stockholder's Deficit compared to December 31, 2024. During the first three months of 2025, Predictive Oncology received more than $3.1 million in combined gross proceeds from the sale to DeRoyal and issuance of common stock. The company also partnered with Switzerland-based Tecan Group Ltd. to expand high-throughput drug screening capabilities, which was showcased at the 2025 Society for Laboratory Automation and Screening International Conference & Exhibition in San Diego, CA. The company is exploring potential partnerships with leading biopharmaceutical companies to leverage its artificial intelligence and machine learning platform for drug repurposing in new cancer indications.

### Related Stocks

- [POAI.US - Predictive Oncology](https://longbridge.com/en/quote/POAI.US.md)
- [AGPU.US - Axe Compute](https://longbridge.com/en/quote/AGPU.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Axe Compute Inc. 任命 Christopher Miglino 为新任首席执行官 | Axe Compute Inc. 任命 Christopher Miglino 为新任首席执行官。Miglino 将领导公司，旨在扩展其去中心化计算平台，并增强其对数字基础设施的承诺。公司计划扩大在去中心化 GPU 计算服务方面的业务，并提 | [Link](https://longbridge.com/en/news/275320870.md) |
| Axe Compute Inc.的董事和首席投资官辞职 | Axe Compute Inc. 宣布三名关键人员辞职：肖恩·马修斯（Shawn Matthews）将于 2026 年 1 月 15 日辞去董事职务，维娜·拉奥（Veena Rao）将于 2026 年 1 月 30 日辞去董事职务，托马斯· | [Link](https://longbridge.com/en/news/273428740.md) |
| Axe Compute Inc. 赞助了在波多黎各举行的 Sequire 投资者峰会 | Axe Compute Inc.（纳斯达克股票代码：AGPU）将赞助定于 2026 年 1 月 20 日至 22 日在圣胡安的康达多万德比尔特酒店举行的 Sequire 投资者峰会。此次峰会将吸引超过 500 名投资者和分析师，以及 75  | [Link](https://longbridge.com/en/news/272282563.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.